Connect with People
The world is a book. Those who do not connect with others miss many pages.
Invite
-
-
-
-
Kevin Doe
Nearly 300
non-invasive diagnostic tests, Claims Roots Analysis
Given the invasive
and cost-intensive nature of tissue biopsies, there is a significant unmet need
for safer and more patient-friendly cancer diagnostics that are capable of
offering highly accurate, and actionable insights related to the disease.
To order this 350+
page report, which features 150+ figures and 200+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/liquid-biopsy-and-nicd-market/279.html
The financial opportunity within the liquid biopsy and
other non-invasive cancer diagnostics market has been analyzed across the
following segments:
§ Type
of Tumor Marker
ctDNA
cfDNA
CTCs
Exosomes
Others
§ Application
Diagnosis / Early Diagnosis
Patient Monitoring
Recurrence Monitoring
§ Target
Cancer Indication
Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Bladder Cancer
Melanoma
Gastric Cancer
Pancreatic Cancer
Ovarian Cancer
Others
§ End Users
Hospitals
Research Institutes
Others
§ Key Geographical Regions
North America
Europe
Asia-Pacific
Rest
of the World
The “Liquid
Biopsy and Other Non-Invasive Cancer Diagnostics Market (3rd Edition),
2019-2030: Focus on Circulating Tumor Markers such as CTCs, ctDNA, cfDNA,
Exosomes and Other Biomarkers.”report features the following companies, which we
identified to be key players in this domain:
§
Amoy Diagnostics
§
DiaCarta
§
HaploX Biotechnology
§
NeoGenomics
§
QIAGEN
§
Swift Biosciences
§
Sysmex Inostics
§
Thermo Fisher Scientific
To request for sample report - https://www.rootsanalysis.com/reports/279/request-sample.html
Table of Contents
1.
Preface
2. Executive Summary
3. Introduction
4. Non-Invasive
Cancer Screening and Diagnosis
5. Market
Landscape
6.
Company Profiles
7.
Partnerships and Collaborations
8.
Funding and Investment Analysis
9. Liquid
Biopsy: Initiatives of Big Pharma Players
10. Key
Acquisition Targets
11.
Other Non-Invasive Cancer Diagnostics
12. Market
Sizing and Opportunity Analysis
13. Survey
Insights
14.
Conclusion
15. Executive
Insights
16.
Appendix 1: Tabulated Data
17.
Appendix 2: List of Companies and Organizations
To purchase a copy,
please visit https://www.rootsanalysis.com/reports/view_document/liquid-biopsy-and-nicd-market/279.html
About Roots Analysis
Roots Analysis is one of the fastest growing
market research companies, sharing fresh and independent perspectives in the
bio-pharmaceutical industry. The in-depth research, analysis and insights are
driven by an experienced leadership team which has gained many years of significant
experience in this sector. If you’d like help with your growing business needs,
get in touch at info@rootsanalysis.com
Other Recent Offerings:
1.
Antibody Drug
Conjugates Market (5th Edition), 2019-2030
2. Gene Therapy Market (3rd Edition), 2019 -
2030
3.
Global T-Cell (CAR-T,
TCR, and TIL) Therapy Market (4th Edition), 2019 – 2030
Contact Information
Roots
Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
ben.johnson@rootsanalysis.com
Facebook - https://www.facebook.com/RootsAnalysis
LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
Twitter
- https://twitter.com/RootsAnalysis
August 23, 2021
-
-
-
-
-
-
Share